Dynavax Technologies Corporation (NASDAQ: DVAX), a developer of innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergy, cancer and chronic inflammatory diseases by utilizing versatile, proprietary approaches to alter immune system responses, recently announced the results form a Phase 3 clinical trial and the company’s second quarter financial results.
Shares of Dynavax Technologies climbed higher earlier this week after the company announced positive top line results from a Phase 3 clinical trial comparing HEPLISAV™, an investigational hepatitis B virus vaccine, to a currently marketed HBV vaccine, GlaxoSmith Kline’s Engerix-B®. This clinical trial showed that 95.1 percent of subjects who received two doses of HEPLISAV™ developed protective antibodies to hepatitis B when measured at 12 weeks. HEPLISAV™ is currently being jointly developed by Dynavax and Merck for use in adults and in patients with end-stage renal disease.
Dynavax Technologies also released financial results for the second quarter ended June 30, 2008. For the quarter, total revenues climbed to $10.0 million, compared to $1.8 million reported for the second quarter of 2007. The increase in revenues for the second quarter reflects the positive impact of research and development funding under a collaboration with Merck for HEPLISAV™. Senior management believe that the company’s ability to support research programs and strategic partnerships with Merck, AstraZeneca and Novartis will continue to support significant revenue growth in the quarters ahead.
Let us hear your thoughts below:
